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EDITORIAL
From the Editor’s Desk: The emergence of
"personalized medicine" in medical care
Medical students throughout their education are
taught to consider the patient as a whole. We are
reminded through our course work and by our course
instructors that understanding the pathophysiologic
basis of disease and responding with clinical
interventions are only part of healing a person who is
ill. So we must consider what makes both the patient
and the disease presenting to us typical. Or better
perhaps would be posing the opposite question: what
makes this patient and their disease different from
others? To be sure, socioeconomic and lifestyle factors,
past medical and family histories, medications, etc. all
contribute to making each patient unique. As editors,
though, we note the emergence of another titratable
parameter in this process of "personalization:" genetic
constitution. We have invited and published in this
issue of the McGill Journal of Medicine, four expert
reviews from leaders in the field of an emerging
approach to medical care referred to as "personalized
medicine." We find them individually well-written and
insightful, and complementary en masse.  
This introductory editorial offers some specific
examples of what we feel are the three most important
elements of this field as presented by the reviews
herein: molecular diagnosis, treatment prediction, and
prognosis-making. With this structure, we hope to
equip the reader with a bird's-eye view of "personalized
medicine," elements of which will be further developed
by the four invited expert reviews herein. We must note
that there is no indexed entry for "personalized
medicine" in the 16th Edition of Harrison's Principles
of Internal Medicine, and that this is very much an
evolving field. In early January, 2007, a PubMed
search for "personalized medicine" returned 532
results, over 80% of which were published after 2000.
Our goal is thus to involve our readers in this dialogue,
by way of introduction, and to empower them to help
chart a course for personalized medicine.  
Personalized medicine aims to consider the genetic
constitution of a patient and their disease in the process
of diagnosis, prognosis, and predicting treatment
response. The process begins with molecular analysis
of the disease entity and patient's genetic constitution,
upon which further subtype diagnosis can sometimes
be made. The utility of molecular diagnosis is
exemplified by defining colorectal cancer subtypes
based on tumorigenic pathways of genetic instability.
It is understood that characteristic serial mutations
frequently underlie the progression of a colorectal
adenoma to an invasive carcinoma - namely, mutations
in tumor-suppressor genes APC, K-ras, and p53. More
recent work has demonstrated that some, about 70%, of
colorectal neoplasia are aneuploid, meaning that they
have an abnormal complement of genetic material in
their neoplastic cells.  Those cancers with
demonstrated aneuploidy states (a state also referred to
as "chromosomal instability") manifest a loss of these
so-called tumor-suppressor genes - that is, a loss of
heterozygosity at this locus - and are designated Group
1 colorectal cancer. Conversely, other forms of
colorectal cancer - the remaining 30% - fail to
demonstrate this aneuploid state in their nuclei. Rather,
in these cancers inactivation of DNA mismatch repair
mechanisms results either from direct mutation of
mismatch repair genes (hereditary non-polyposis
colorectal cancer or Lynch Syndrome) or from
hypermethylation of CpG islands in the promoters that
drive the expression of these mismatch repair genes,
thus attenuating their expression (Group 2). Clinically,
Groups 1 and 2 colorectal cancers differ in many
important ways. One prominent difference is that
Group 1 colorectal cancers are mainly well to
moderately differentiated adenocarcinomas (invasive
cancer of glandular cells), whereas Group 2 cancers are
generally more poorly differentiated, and associated
with a poorer prognosis. Molecular diagnosis of
colorectal neoplasms is therefore becoming a focus of
not only diagnosis, but could also provide substrate for
subtype-specific treatment design and prognosis-
making. Such analysis is an example of "molecular
diagnosis," and is an important component of
personalized medicine. 
Another important concept under the umbrella of
"personalized medicine" is predicting treatment
response based on molecular diagnosis. Several new
pharmaceuticals have emerged very recently that are
referred to as "targeted therapies." Perhaps the best-
known example is that of the monoclonal antibody
trastuzumab (Herceptin®). Trastuzumab has offered
great promise to many women with a sub-type of
invasive breast cancer. Invasive breast cancer is most
frequently ductal (80%) or lobular (10%) carcinoma,
and is believed to arise from a progression that includes
carcinoma in situ.  Treatment generally consists of
local - radiation-based and surgical - and systemic -
chemotherapeutic, including the microtubule-
stabilizing drug paclitaxel - treatments. The toxicity of
systemic chemotherapeutic drugs can be high, and is
largely due to systemic inhibition of more rapidly
proliferating tissues: bone marrow suppression,
gastrointestinal dysfunction, hair loss. Trastuzumab2 McGill Journal of Medicine 2007
was developed based on the observation that some
breast carcinomas appear to have evolved in part due to
an over-expression of the epidermal growth factor
receptor 2 (HER2).  Over-sensitivity through over-
expression of the receptor HER2 leads to excess cell
stimulation of cell proliferation, the hallmark of cancer.
Trastuzumab is a purified human monoclonal antibody
that inhibits the dimerization of the tyrosine kinase
subunits of the HER2 protein.  Patients are tested to
determine if their cancer is HER2-positive, using one
of two tests approved by the American Food and Drug
Administration: immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH). Thus, by
specifically targeting an important basis of this subtype
of breast carcinoma, physicians can predict if a patient
will likely respond to trastuzumab treatment, and can
improve outcomes for many of these patients. A similar
mechanism of action - inhibition of receptor tyrosine
kinase activity - underlies the beneficial effects of
another anti-cancer drug, imatinib mesylate
(Gleevec®), which has shown great success in
treatment of Philadelphia-chromosome positive
chronic myelogenous leukemia (CML). To many, these
drugs represent a thrust of cancer biology, and underlie
the mantra of physician-scientists: "from bench to
bedside." 
The third constituent of the approach underlying
"personalized medicine" is prognosis. Here again, the
reader can find examples of the utility of personalized
medicine in the management of breast cancer patients.
Prognostic value of molecular diagnosis is well
established in the case of the her2/neu mutation that
underlies HER2-positive invasive breast cancers -
which are found in about 20 to 25% of breast cancers,
according to the American Association for Cancer
Research. Studies have demonstrated that HER-2/neu
amplification is an independent predictor of shorter
disease free survival in both node-negative and node-
positive patients,  and hence confers a worse prognosis.
HER2-positive breast cancer and Herceptin are
discussed in depth by the reviews herein. 
This rationale behind personalized medicine is
tantalizing, as it elegantly integrates a seemingly
discursive body of knowledge about pathology,
genetics, and pharmacology into a clear improvement
in treatment options for patients - many of whom with
significantly morbid and mortal diseases. This is a
beginning for personalized medicine, though: whether
these drugs and diagnostics herald the beginning of an
era of new genetically-tailored drugs, or instead are
"beginner's luck" innovations for doctors and scientists,
remains to be seen. We hope that this arguably agnostic
conclusion is not disappointing to the reader: we feel
that it will be up to the reader to consider personalized
medicine as an emergent approach to medical care. We
hope that the four articles herein will provide sufficient
flint and steel to spark such a discourse on this topic for
you, and will invite perspective on what helps define
the patient and their disease. Please enjoy these reviews
- and all the excellent articles in this issue of the MJM
- and accept our warm wishes. 
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